Dergi makalesi Açık Erişim
Eren, Selen Abanuz; Tastan, Cihan; Karadeniz, Kevser Buse; Turan, Raife Dilek; Cakirsoy, Didem; Kancagi, Derya Dilek; Yilmaz, Sevdican Ustun; Oztatlici, Mustafa; Oztatlici, Hulya; Ozer, Samed; Tumentemur, Gamze; Baykal, Ahmet Tarik; Ovali, Ercument
<?xml version='1.0' encoding='UTF-8'?> <record xmlns="http://www.loc.gov/MARC21/slim"> <leader>00000nam##2200000uu#4500</leader> <datafield tag="700" ind1=" " ind2=" "> <subfield code="a">Tastan, Cihan</subfield> </datafield> <datafield tag="700" ind1=" " ind2=" "> <subfield code="a">Karadeniz, Kevser Buse</subfield> <subfield code="u">Acibadem Labcell Cellular Therapy Lab, Istanbul, Turkiye</subfield> </datafield> <datafield tag="700" ind1=" " ind2=" "> <subfield code="a">Turan, Raife Dilek</subfield> <subfield code="u">Yeditepe Univ, Dept Genet & Bioengn, Istanbul, Turkiye</subfield> </datafield> <datafield tag="700" ind1=" " ind2=" "> <subfield code="a">Cakirsoy, Didem</subfield> <subfield code="u">Acibadem Labcell Cellular Therapy Lab, Istanbul, Turkiye</subfield> </datafield> <datafield tag="700" ind1=" " ind2=" "> <subfield code="a">Kancagi, Derya Dilek</subfield> <subfield code="u">Acibadem Labcell Cellular Therapy Lab, Istanbul, Turkiye</subfield> </datafield> <datafield tag="700" ind1=" " ind2=" "> <subfield code="a">Yilmaz, Sevdican Ustun</subfield> <subfield code="u">Acibadem Mehmet Ali Aydinlar Univ, Inst Hlth Sci, Med Biotechnol Dept, Istanbul, Turkiye</subfield> </datafield> <datafield tag="700" ind1=" " ind2=" "> <subfield code="a">Oztatlici, Mustafa</subfield> <subfield code="u">Gaziantep Islam Sci & Technol Univ, Fac Med, Dept Histol & Embryol, Gaziantep, Turkiye</subfield> </datafield> <datafield tag="700" ind1=" " ind2=" "> <subfield code="a">Oztatlici, Hulya</subfield> <subfield code="u">Gaziantep Univ, Fac Med, Dept Histol & Embryol, Gaziantep, Turkiye</subfield> </datafield> <datafield tag="700" ind1=" " ind2=" "> <subfield code="a">Ozer, Samed</subfield> <subfield code="u">Acibadem Mehmet Ali Aydinlar Univ, Anim Applicat & Res Ctr, Istanbul, Turkiye</subfield> </datafield> <datafield tag="700" ind1=" " ind2=" "> <subfield code="a">Tumentemur, Gamze</subfield> <subfield code="u">Acibadem Mehmet Ali Aydinlar Univ, Vocat Sch Hlth Serv, Istanbul, Turkiye</subfield> </datafield> <datafield tag="700" ind1=" " ind2=" "> <subfield code="a">Baykal, Ahmet Tarik</subfield> <subfield code="u">Acibadem Mehmet Ali Aydinlar Univ, Inst Hlth Sci, Dept Biochem & Mol Biol, Istanbul, Turkiye</subfield> </datafield> <datafield tag="700" ind1=" " ind2=" "> <subfield code="a">Ovali, Ercument</subfield> <subfield code="u">Acibadem Labcell Cellular Therapy Lab, Istanbul, Turkiye</subfield> </datafield> <datafield tag="909" ind1="C" ind2="4"> <subfield code="p">CURRENT GENE THERAPY</subfield> <subfield code="v">23</subfield> <subfield code="n">4</subfield> <subfield code="c">12</subfield> </datafield> <datafield tag="980" ind1=" " ind2=" "> <subfield code="a">user-tubitak-destekli-proje-yayinlari</subfield> </datafield> <datafield tag="540" ind1=" " ind2=" "> <subfield code="a">Creative Commons Attribution</subfield> <subfield code="u">http://www.opendefinition.org/licenses/cc-by</subfield> </datafield> <datafield tag="024" ind1=" " ind2=" "> <subfield code="a">10.2174/1566523223666230407091317</subfield> <subfield code="2">doi</subfield> </datafield> <datafield tag="245" ind1=" " ind2=" "> <subfield code="a">Lentiviral Micro-dystrophin Gene Treatment into Late-stage mdx Mice for Duchenne Muscular Dystrophy Disease</subfield> </datafield> <datafield tag="100" ind1=" " ind2=" "> <subfield code="a">Eren, Selen Abanuz</subfield> </datafield> <datafield tag="909" ind1="C" ind2="O"> <subfield code="o">oai:aperta.ulakbim.gov.tr:266424</subfield> <subfield code="p">user-tubitak-destekli-proje-yayinlari</subfield> </datafield> <datafield tag="650" ind1="1" ind2="7"> <subfield code="2">opendefinition.org</subfield> <subfield code="a">cc-by</subfield> </datafield> <datafield tag="260" ind1=" " ind2=" "> <subfield code="c">2023-01-01</subfield> </datafield> <datafield tag="856" ind1="4" ind2=" "> <subfield code="u">https://aperta.ulakbim.gov.trrecord/266424/files/bib-46840d36-3fb1-495b-92b9-76dec55e4a9c.txt</subfield> <subfield code="z">md5:733be9c6d9009e1deef6d6cb6b8d3c33</subfield> <subfield code="s">323</subfield> </datafield> <datafield tag="542" ind1=" " ind2=" "> <subfield code="l">open</subfield> </datafield> <controlfield tag="005">20240607120842.0</controlfield> <controlfield tag="001">266424</controlfield> <datafield tag="980" ind1=" " ind2=" "> <subfield code="a">publication</subfield> <subfield code="b">article</subfield> </datafield> <datafield tag="520" ind1=" " ind2=" "> <subfield code="a"><p>Aim Duchenne Muscular Dystrophy (DMD) results in a deficiency of dystrophin expression in patient muscle fibers, leading to progressive muscle degeneration. Treatment of DMD has undertaken current transformation with the advancement of novel gene therapy and molecular biology techniques, which are secure, well-tolerated, and effective therapeutic approaches. Introduction DMD gene therapies have mainly focused on young DMD patients as in vivo animal model trials have been performed in 0-1-month DMD mice. However, it has not yet been answered how micro-dystrophin encoding lentiviral treatment affects Dystrophin expression and DMD symptoms in 10-month mdx mice. Methods We planned to integrate the micro-Dystrophin gene sequence into the muscle cells by viral transfer, using micro-Dystrophin-encoding lentivirus to reduce the dystrophic pathology in late-stage dmd mice. The histopathological and physiological-functional regeneration activities of the lentiviral-micro-Dystrophin gene therapy methods were compared, along with changes in temporal Dystrophin expression and their functionality, toxicity, and gene expression level. Results Here, we showed that the micro-dystrophin transgene transfers intramuscularly and intraperitoneally in late-stage dmd-mdx-4cv mice restored dystrophin expression in the skeletal and cardiac muscle (p &lt;0.001). Furthermore, motor performance analysis, including hanging and tracking tests, improved statistically significantly after the treatment (p &lt;0.05). Conclusion Consequently, this study suggests that patients in the late stages of muscular dystrophy can benefit from lentiviral micro-dystrophin gene therapies to present an improvement in dystrophic muscle pathology.</p></subfield> </datafield> </record>
Görüntülenme | 2 |
İndirme | 0 |
Veri hacmi | 0 Bytes |
Tekil görüntülenme | 2 |
Tekil indirme | 0 |